Apogee TherapeuticsAPGE
APGE
About: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
Employees: 196
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
57% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 21
50% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $9.54M
6% more funds holding
Funds holding: 157 [Q4 2024] → 167 (+10) [Q1 2025]
5.09% more ownership
Funds ownership: 128.52% [Q4 2024] → 133.61% (+5.09%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
12% less capital invested
Capital invested by funds: $2.62B [Q4 2024] → $2.3B (-$320M) [Q1 2025]
14% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 58
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$116
204%
upside
Avg. target
$116
204%
upside
High target
$116
204%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Seamus Fernandez | 204%upside $116 | Buy Reiterated | 2 Jul 2025 |
Financial journalist opinion
Based on 5 articles about APGE published over the past 30 days
Positive
Seeking Alpha
5 days ago
Apogee Therapeutics: Funding Supports Best-In-Class Ambitions In Atopic Dermatitis
Apogee Therapeutics, Inc.'s APG777 shows best-in-class week-16 efficacy and quarterly/semi-annual dosing potential. In my view, this could give this drug candidate a great competitive profile. In fact, APG777 could potentially disrupt the massive AT market, which is currently dominated by Dupixent. APGE's Phase 2 trial, called APEX Part A, exceeded its targets. We also have to wait until 1H2026 for its maintenance data. Part B efficacy data is due by mid-2026.
Positive
Proactive Investors
6 days ago
Apogee Therapeutics reports positive Phase 2 results for atopic dermatitis drug
Apogee Therapeutics (NASDAQ:APGE) shares fell almost 15% despite the release of positive Phase 2 APEX trial results for APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial met its primary endpoint with a 71% reduction in Eczema Area Severity Index (EASI) score at Week 16, versus 33.8% for placebo.
Negative
Investors Business Daily
6 days ago
Apogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a quarterly or twice-yearly shot to control eczema.
Neutral
GlobeNewsWire
6 days ago
Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 7 1.0% decrease from baseline in EASI at Week 16
Neutral
GlobeNewsWire
1 week ago
Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025
SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced it will report Part A 16-week data from the Phase 2 APEX trial of APG777 on Monday, July 7, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
1 month ago
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Seeking Alpha
2 months ago
Apogee Therapeutics: APG808 Asthma Treatment May Overtake Dupixent In IL-4Rα Class
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.
Neutral
GlobeNewsWire
2 months ago
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
Charts implemented using Lightweight Charts™